On December 8, China embarked on its inaugural precision radiotherapy IIT study targeting brain metastases—the ZAP-X IIT study, which is being conducted at Xuanwu Hospital, affiliated with Capital Medical University. This collaborative research effort between Xuanwu Hospital and BAHEAL Pharmaceutical is spearheaded by Zhang Hongqi, the head of the Department of Neurosurgery at Xuanwu Hospital. The primary objective of this study is to assess the clinical effectiveness, safety profile, and dosimetric attributes of the ZAP-X radiosurgery robot when utilized for treating brain metastases. The study is bolstered by academic guidance from the Chinese Collaborative Group for Intracranial Metastases, while the Department of Neurosurgery at Xuanwu Hospital takes charge of its inception and execution. The ZAP-X device, a brainchild of Professor John Adler, is tailored specifically for delivering precise radiotherapy to the brain.